Efficacy and safety of risperidone in the treatment of schizoaffective disorder: Initial results from a large, multicenter surveillance study

Journal of Clinical Psychiatry

Volumn 62, Issue 8, 2001, Pages 623-630

  Vieta, E ^a   Herraiz, M ^a   Fernandez A ^a   Gasto C ^a   Benabarre, A ^a   Colom, F ^a   Martinez Aran A ^a   Reinares, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; FLUVOXAMINE MALEATE; HALOPERIDOL; MIRTAZAPINE; OLANZAPINE; PIMOZIDE; RISPERIDONE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RATING SCALE; RISK BENEFIT ANALYSIS; SCHIZOIDISM; TARDIVE DYSKINESIA;

EID: 0034856341     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n0809     Document Type: Article

References (48)

1. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
2. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis
3. Risperidone in the treatment of schizophrenia
4. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
5. Psychopathology of schizophrenia: Initial validation of a five-factor model
6. Effects of risperidone on affective symptoms in patients with schizophrenia
7. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series
8. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
9. Risperidone therapy in treatment-refractory acute bipolar and schizoaffective mania
10. Risperidone in the treatment of mania
11. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
12. Treatment of refractory rapid cycling bipolar disorder with risperidone
13. Long-term risperidone treatment in bipolar disorder: 6-months follow-up
14. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomised controlled trial
15. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
16. Induction of mania by risperidone resistant to mood stabilisers
17. Problemas de evaluación en trastornos del humor
18. The role of risperidone in bipolar II: An open six-month study
19. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder
20. A rating scale for mania: Reliability, validity, and sensitivity
21. Development of a rating scale for primary depressive illness
22. The UKU Side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
23. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia
24. Course of the manic-depressive cycle and changes caused by treatment
25. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants
26. Can antidepressants cause mania and worsen the course of affective illness?
27. Tardive dyskinesia as a life-threatening illness
28. Neurologic symptoms in pharmacotherapy of the psychoses
29. Tardive dyskinesia: Prevalence, incidence, and risk factors
30. Tardive dyskinesia in bipolar affective disorder
31. Affective disorders and tardive dyskinesia
32. Tardive dyskinesia
33. Long-term treatment of mood disorders in schizophrenia
34. Depression and social adjustment among chronic schizophrenic outpatients
35. The complex problem of treatment
36. Excess mortality of schizophrenia: A meta-analysis
37. Can risperidone be antidepressive and also inhibit aggression?
38. 2-adrenoceptor antagonism
39. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine
40. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States
41. Medical comorbidity in schizophrenia
42. Safety of olanzapine
43. Extrapyramidal symptoms in patients treated with risperidone
44. Drug safety: Experience with risperidone